1. Scrip
  2. >>Business
  3. >>Financing

ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates

Next-Gen Cell Therapy Firm Aims To Solve First-Gen Problems

 
• By Mandy Jackson

ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment. 

Blue background with wooden gears. Mind works and new ideas concept.
ImmPACT raised $111m to advance its three big ideas for improving CAR-T therapies • Source: Alamy

ImmPACT Bio USA emerged from the FutuRx incubator in Israel in 2017 to develop chimeric antigen receptor T-cell (CAR-T) therapies that could be effective against solid tumors. Now, with $111m in series B venture capital announced on 20 January, ImmPACT aims to build out its three separate technology platforms that are designed to solve multiple first-generation CAR-T problems.

Now based in Camarillo, CA, ImmPACT incorporated in the US in 2019, raised an $18m series A round in 2020 and merged with University of California, Los Angeles (UCLA) spin-out Kalthera, Inc. in July of last year. (Also see "Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal" - Scrip, 9 August, 2021

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

 
• By Mandy Jackson

Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.

More from Business

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.